AU2005275183B2 - Oxazole derivatives as histamine H3 receptor agents, preparation and therapeutic uses - Google Patents

Oxazole derivatives as histamine H3 receptor agents, preparation and therapeutic uses Download PDF

Info

Publication number
AU2005275183B2
AU2005275183B2 AU2005275183A AU2005275183A AU2005275183B2 AU 2005275183 B2 AU2005275183 B2 AU 2005275183B2 AU 2005275183 A AU2005275183 A AU 2005275183A AU 2005275183 A AU2005275183 A AU 2005275183A AU 2005275183 B2 AU2005275183 B2 AU 2005275183B2
Authority
AU
Australia
Prior art keywords
methyl
ethyl
pyrrolidin
oxazol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005275183A
Other languages
English (en)
Other versions
AU2005275183A1 (en
Inventor
Lisa Selsam Beavers
Serge Louis Boulet
Terry Patrick Finn
Robert Alan Gadski
William Joseph Hornback
Cynthia Darshini Jesudason
Richard Todd Pickard
Freddie Craig Stevens
Grant Matthews Vaught
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2005275183A1 publication Critical patent/AU2005275183A1/en
Application granted granted Critical
Publication of AU2005275183B2 publication Critical patent/AU2005275183B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2005275183A 2004-07-26 2005-07-14 Oxazole derivatives as histamine H3 receptor agents, preparation and therapeutic uses Ceased AU2005275183B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59119104P 2004-07-26 2004-07-26
US60/591,191 2004-07-26
PCT/US2005/024883 WO2006019833A1 (en) 2004-07-26 2005-07-14 Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses

Publications (2)

Publication Number Publication Date
AU2005275183A1 AU2005275183A1 (en) 2006-02-23
AU2005275183B2 true AU2005275183B2 (en) 2011-03-17

Family

ID=35134220

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005275183A Ceased AU2005275183B2 (en) 2004-07-26 2005-07-14 Oxazole derivatives as histamine H3 receptor agents, preparation and therapeutic uses

Country Status (17)

Country Link
US (1) US7666871B2 (enExample)
EP (1) EP1786790B1 (enExample)
JP (1) JP4982367B2 (enExample)
CN (1) CN1989115B (enExample)
AT (1) ATE432926T1 (enExample)
AU (1) AU2005275183B2 (enExample)
BR (1) BRPI0513777A (enExample)
CA (1) CA2575081C (enExample)
CY (1) CY1109493T1 (enExample)
DE (1) DE602005014786D1 (enExample)
DK (1) DK1786790T3 (enExample)
ES (1) ES2325865T3 (enExample)
MX (1) MX2007001029A (enExample)
PL (1) PL1786790T3 (enExample)
PT (1) PT1786790E (enExample)
SI (1) SI1786790T1 (enExample)
WO (1) WO2006019833A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008301B2 (en) * 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
US7728009B1 (en) 2005-02-18 2010-06-01 Neurogen Corporation Thiazole amides, imidazole amides and related analogues
CA2602336A1 (en) * 2005-03-31 2006-10-05 Ucb Pharma S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
TWI330639B (en) 2005-11-15 2010-09-21 Otsuka Pharma Co Ltd Oxazole compound and pharmaceutical composition
WO2007108936A2 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
CA2649913A1 (en) 2006-05-19 2007-11-29 Wyeth N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
WO2007134971A1 (de) * 2006-05-19 2007-11-29 Basf Se Benzoylsubstituierte alanine
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
CA2693138A1 (en) 2007-07-16 2009-01-22 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
WO2009126782A1 (en) * 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
US8383829B2 (en) * 2008-04-15 2013-02-26 Konica Minolta Holdings, Inc. Electrochromic compound, electrode, and display element
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
EA201291384A1 (ru) 2010-07-06 2013-07-30 Астразенека Аб Терапевтические агенты 976
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US9156831B2 (en) 2013-01-23 2015-10-13 Astrazeneca Ab Chemical compounds
WO2016097071A1 (en) * 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
HRP20191327T1 (hr) 2015-06-03 2019-11-01 Bristol Myers Squibb Co 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primjenju u liječenju kardiovaskularnih poremećaja
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
HRP20220223T1 (hr) 2017-01-11 2022-04-29 Alkermes, Inc. Biciklički inhibitori histon deacetilaze
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819037A1 (de) * 1988-06-04 1989-12-14 Hoechst Ag 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden
WO2005040158A1 (en) * 2003-10-24 2005-05-06 F. Hoffmann - La Roche Ag 1-′(e)-2-(phenyl) ethenyl-4-(arylalkoxy)-oxazole or - thiazole compounds as her-2 tyrosine kinases inhibitors and their use in the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU674613B2 (en) * 1993-09-28 1997-01-02 Otsuka Pharmaceutical Co., Ltd. Quinoxaline derivative as antidiabetic agent
WO2000064884A1 (en) * 1999-04-26 2000-11-02 Novo Nordisk A/S Piperidyl-imidazole derivatives, their preparations and therapeutic uses
JP2004532834A (ja) 2001-03-23 2004-10-28 イーライ・リリー・アンド・カンパニー ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
WO2003064411A1 (en) 2002-02-01 2003-08-07 Novo Nordisk A/S Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819037A1 (de) * 1988-06-04 1989-12-14 Hoechst Ag 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden
WO2005040158A1 (en) * 2003-10-24 2005-05-06 F. Hoffmann - La Roche Ag 1-′(e)-2-(phenyl) ethenyl-4-(arylalkoxy)-oxazole or - thiazole compounds as her-2 tyrosine kinases inhibitors and their use in the treatment of cancer

Also Published As

Publication number Publication date
CY1109493T1 (el) 2014-08-13
PT1786790E (pt) 2009-08-18
CN1989115B (zh) 2012-03-21
SI1786790T1 (sl) 2009-10-31
AU2005275183A1 (en) 2006-02-23
EP1786790A1 (en) 2007-05-23
JP4982367B2 (ja) 2012-07-25
WO2006019833A1 (en) 2006-02-23
BRPI0513777A (pt) 2008-05-13
US7666871B2 (en) 2010-02-23
DK1786790T3 (da) 2009-07-20
DE602005014786D1 (de) 2009-07-16
CA2575081A1 (en) 2006-02-23
ATE432926T1 (de) 2009-06-15
MX2007001029A (es) 2007-04-12
CA2575081C (en) 2013-05-07
PL1786790T3 (pl) 2009-10-30
EP1786790B1 (en) 2009-06-03
CN1989115A (zh) 2007-06-27
ES2325865T3 (es) 2009-09-22
US20070197604A1 (en) 2007-08-23
JP2008507579A (ja) 2008-03-13

Similar Documents

Publication Publication Date Title
CA2575081C (en) Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
AU2005277518B2 (en) Histamine H3 receptor agents, preparation and therapeutic uses
CN109153649B (zh) 烟碱乙酰胆碱受体的变构调节剂
US11046680B1 (en) Heteroaryl-substituted triazoles as APJ receptor agonists
WO2007126043A1 (ja) チアゾール環を含むカルボン酸誘導体の医薬用途
AU5731099A (en) Substituted oxazoles and thiazoles derivatives as hppar gamma and hppar alpha activators
WO2007078523A2 (en) 5-phenyl-3-benzyl-0xaz0lidin-2-0ne derivatives and related compounds as metabotropic glutamate receptor potentiators for the treatment of neurological and psychiatric disorders
CA2510793A1 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
BG108597A (bg) Антидиабетични средства за орално приложение
JP2010533725A (ja) ヒスタミン‐３（ｈ３）受容体としてのアミノアルキルアゾール化合物
MX2015002624A (es) Nuevas tiofenilamidas no anuladas como inhibidores de las proteinas de union a acido graso (fabp) 4 y/o 5.
WO2006049232A1 (ja) チアゾール環を含むカルボン酸誘導体およびその医薬用途
EP2459554B1 (en) Substituted benzamide derivatives as glucokinase (gk) activators
HK1156254A (zh) 抗菌剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired